

US007022674B2

(12) United States Patent

DeFelippis et al.

(10) Patent No.: US 7,022,674 B2

(45) Date of Patent:

Apr. 4, 2006

(54) POLYPEPTIDE COMPOSITIONS WITH IMPROVED STABILITY

(75) Inventors: **Michael Rosario DeFelippis**, Carmel, IN (US); **Michael Allen Dobbins**,

Lebanon, IN (US); Alby David Sharknas, Indianapolis, IN (US); Alex Mark Prokai, Carmel, IN (US); Joseph Vincent Rinella, Ypsilanti, MI (US)

(73) Assignee: Eli Lilly and Company, Indianapolis,

IN (US)

(*) Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 509 days.

(21) Appl. No.: 10/130,836

(22) PCT Filed: Dec. 5, 2000

(86) PCT No.: PCT/US00/32421

§ 371 (c)(1),

(2), (4) Date: May 21, 2002

(87) PCT Pub. No.: WO01/43762

PCT Pub. Date: Jun. 21, 2001

(65) Prior Publication Data

US 2003/0207802 A1 Nov. 6, 2003

Related U.S. Application Data

- (60) Provisional application No. 60/181,030, filed on Feb. 8, 2000, provisional application No. 60/171,135, filed on Dec. 16, 1999.
- (51) **Int. Cl. A61K 38/00** (2006.01)
- (52) **U.S. Cl.** 514/12; 514/3

(56) References Cited

U.S. PATENT DOCUMENTS

4,076,758 A	2/1978	Owsley et al.
4,683,347 A	7/1987	Diaz et al.
5,124,314 A	6/1992	Cooper
5,164,366 A	11/1992	Balschmidt et al.
5,514,646 A	5/1996	Chance et al.
5,618,913 A	4/1997	Brange et al.
5,750,166 A	5/1998	Schellhaass
5,951,993 A	9/1999	Scholz et al.
5,969,175 A	10/1999	Murao et al.
6,034,054 A *	3/2000	DeFelippis et al 514/4
6,136,784 A	10/2000	L'italien et al.
6,268,343 B1*	7/2001	Knudsen et al 514/12

FOREIGN PATENT DOCUMENTS

CA	2242591	7/1998
DK	173015 B1	6/1996
EP	0 849 276 A1	12/1997
EP	0 885 961 A1	6/1998
WO	WO 97/48414	12/1997
WO	WO 98/21340	5/1998
WO	WO 99/28480	6/1999
WO	WO 99/29336	6/1999
WO	WO 99/29337	6/1999
WO	WO 99/43708	9/1999
WO	WO 00/07617	2/2000
WO	WO 00/38652	7/2000
WO	WO 00/41546	7/2000

OTHER PUBLICATIONS

Peter Klusmann, Novo Nordisk, Grounds for Appeal filed with the German Federal Patent Court Against the German Patent Office in Proceedings relating to the German Utility Model that Corresponds to this U.S. Appl. No. 10/130,836, filed Dec. 17, 2004.*

Rohde, T.D., et al., "An Improved Glycerol/Insulin Formulation for Use in Implant not Pumps", Trans Ams Soc Artif Intern Organs, vol. 33, 1987, pp. 316-318.

Washabaugh M.W. et al., "Purfication of Aqueous Ethylene Glycol", Analytical Biochemistry, vol. 134, 1983, pp. 144-152.

Bello J. et al., "Chemical Modification and Cross-Linking of Proteins by Impurities in Glycerol", Archives of Biochemistry and Biophysics, vol. 172, 1976, pp. 608-610. Robbins D.C. et al., "Antibodies to Covalent Aggregates of Insulin in Blood of Insulin-Using Diabetic Patients", Diabetes, vol. 36, 1987, pp. 838-841.

Robbins D.C. et al., "Free Covalent Aggregates of Therapeutic Insulin in Blood of Insulin-Dependent Diabetics", Diabetes, vol. 36, 1987, pp. 147-151.

Ratner et al., "Persistent Cutaneous Insulin Allergy Resulting From High-Molecular-Weight Insulin Aggregates", Diabetes, vol. 39, 1990, pp. 728-733.

(Continued)

Primary Examiner—Christopher R. Tate Assistant Examiner—Marcela M Cordero Garcia (74) Attorney, Agent, or Firm—Thomas E. LaGrandeur; James A. Hoffmann; James J. Kelley

(57) ABSTRACT

The present invention provides means to improve the chemical stability of aqueous, parenteral pharmaceutical compositions comprising a polypeptide and glycerin. Reactive aldehydes are identified in commercial glycerins, and means for reducing such are provided. Convenient means are provided to assay for reactive aldehydes in glycerin, and a strong linear correlation between the level of reactive aldehydes in glycerin and chemical stability of compositions comprising a polypeptide and glycerin is demonstrated. The invention includes aqueous compositions comprising a polypeptide and glycerin having improved chemical stability compared to compositions previously known.



OTHER PUBLICATIONS

Brange J, et al., "Chemical Stability of Insulin. 2 Formation of Higher Molecular Weight Transformation Products During Storage of Pharmaceutical Preparations", Pharmaceutical Research, vol. 9, 1992, pp. 727-734.

Schwendeman S.P. et al., "Stabilization of Tetanus and Diphtheria Toxoids Against Moisture-Induced Aggregation", Proc. Natl. Acad Sci. USA, vol. 92, 1995, pp. 11234-11238

Fraenkel-Conrat H. et al., "The Reaction of Formaldehyde With Proteins. V. Cross-Linking Between Amino and Guanidyl Groups", JACS, vol. 70, 1948, pp. 2673-2684.

Seetharama Acharya A. et al., "Reaction Of Glycolaldehyde With Proteins: Latent Crosslinking Potential of ∝—Hydroxyaldehydes", Proc. Natl. Acad. Sci. USA, vol. 80, 1983, pp. 3590-3594.

Seetharama Acharya A. et al., "Cross-Linking of Proteins by Aldotriose: Reaction of the Carbonyl Function of the Keto Amines Generated in Situ With Amino Groups", Biochemistry, vol. 27, 1988, pp. 4522-4529.

Brange J., Stability of Insulin, Kluwer Academic Publishers, Boston, 1994, pp. 23-36.

Brange J., et al., "Formulation of Physically Stable Neutral Insulin Solutions for Continuous Infusion by Delivery Systems", Hormone Drugs, Published by the US Pharmacopoeial Convention, Rockville, Maryland, 1982, pp. 96-105.

The European Pharmacopoeia Supplement 2000, Council of Europe, Strasbourg, France, 1999, pp. 747-750.

The British Pharmacopoeia, British Pharmacopoeia Commission, London, 1999, vol. 1, pp. 710-711.

Dickinson R.G. et al., "A New Sensitive and Specific Test for the Detection of Aldehydes: Formation of 6-Mercapto-3Substituted-s-Triazolo(4,3-b)-s Tetrazines", Chemical Communications, 1970, pp. 1719-1720.

Aldrich Technical Information Bulletin No. AL-145, Aldrich Chemical Co,; Hopps, H.B., Aldrichimica Acta 33:28-29, 2000.

Nash, T., "The Colorimetric Estimation of Formaldehyde by Means of the Hantzsch Reaction", Biochem. J., vol. 55, 1953, pp. 416-421.

The International Pharmacipoeia, Third Edition, vol. 4, 1994, pp. 176-181.

Promotional Bulletin Entitled "Discover the Origins of Some of the World's Most Consistently Pure Products; Synthetic Glycerine Products", by Dow Chemical Company—Freeport, TX, USA, pp. 1-32.

Sawicki E., et al., "The 3-Methyl-2-Benzothiazolone Hydrazone Test", Analytical Chemistry, vol. 33, 1961, pp. 93-96

Paz, M.A., et al., "Determination of Carbonyl Compounds with N-Methyl Benzothiazolone Hydrazone", Archives of Biochemistry and Biophysics, vol. 109, 1965, pp. 548-559. Eberhardt M.A. et al., "A Colorimetric Procedure for the Determination of Aldehydes in Seawater and in Cultures of Methylotrophic Bacteria", Marine Chemistry, vol. 17, 1985, pp. 199-212.

Glutaraldehyde Test Kit, Model GT-1, Cat. No. 25872-00, by Hach, Loveland, CO, USA.

Bailey B.W. et al., "New Spectrophotometric Method for Determination of Formaldehyde", Analytical Chemistry, vol. 43, 1971, pp. 782-784.

Ziels N.W. et al., "Recovery and Purification of Glycerol", The Journal of the American Oil Chemists Society, vol. 23 Bello J., "The State of the Tyrosines of Bovine Pancreatic Ribonuclease in Ethylene Glycol and Glycerol", Biochemistry, vol. 8, 1969, pp. 4535-4541.

Riddick J.A. et al., "Organic Solvents", Techniques of Chemistry, vol. 2, Third Edition, pp. 689-691.

Stromquist D.M. et al., "C.P. Glycerol by Ion Exchange", Industrial and Engineering Chemistry, vol. 43, 1951, pp. 1065-1070.

Encyclopedia of Chemical Technology, Fourth Edition, Kirk Othmer, vol. 12, Glycerol, 1994, pp. 681-694.

Remington's Pharmaceutical Sciences, Mack Publishing Company, 18th Edition, 1990, Chapter 66, pp. 1316.

Food Engineering, International Edition, Chilton Company, 1997, p. 14.

Knudsen L.B. et al., "Potent Derivatives of Glucagon-Like Peptide-1 with Pharmacokinetic Properties Suitable for Once Daily Administration", Expedited Articles, Journal of Medical Chemistry, vol. 43, 2000, pp. 1664-1669.

Shome B. et al., "A Reevaluation of the Amino Acid Sewuence of Human Follitropin β -Subunit", Journal of Protein Chemistry, vol. 7, 1988, pp. 325-339.

The United States Pharmacopeia, The National Formulary, United States Pharmacopeial Convention, Inc. 2000, USP 24, NF 19.

Underberg W.J.M. et al., "Separation and Detection Tecniques for Peptides and Proteins in Stability Research and Bioanalysis", Journal of Chromatography B, vol. 742, 2000, pp. 401-409.

Brange J., Galenics of Insulin, Springer-Verlag 1987.

Du Chatinier W.M. et al., "Rapid Stability Indicating UV-Assay of Methenamine Madelate in Tablets Using Solid Phase Extraction", Analytical Letters, vol. 22, 1989, pp. 875-883.

European Pharmacopoeia, Council of Europe, Strasbourg, 1997, pp. 906-907.

Roach P. et al., "Improved Postprandial Glycemic Control During Treatment with Humalog Mix25, A Novel Protamine-Based Insulin Lispro Formulation", Diabetes Care, vol. 22, 1999, pp. 1258-1261.

Peter Schindler, Certificate fom Merck KGaA, Darmstadt, Germany (2001).

Havelund S and Brange J, Abstract, Second Assisi International Symposium, Chemical Stabilization of Insulin-Glycerol Mixtures, Novo Research Institute, Bagsvaerd Denmark (1986).

Ja Rozandeal, Vector Control—Methods for Use by Individuals and Communities, pps 505-513, (1997).


J. Brange, et al., Chemical Stability of Insulin, Acta Pharm., 4(3) 149-155 (1992).

Ullmann's Encyclopeida of Industrial Chemistry, Fifth, Completely Revised Edition, vol. A12.

S. Haveland and J. Brange, Poster Second Assisi International Symposium, Chemical Stabilization of Insulin-Glycerol Mixtures, (1986).

Peter Klusmann, Novo Nordisk, Grounds for Appeal filed with the German Federal Patent Court Against the German Patent Office in Proceedings relating to the German Utility Model that Corresponds to this *U.S. Appl. No. 10/130,836. German Original, English Translation, and Original Cited Supporting Documents.* (Dec. 17, 2004).







1

POLYPEPTIDE COMPOSITIONS WITH IMPROVED STABILITY

This application is a United States national stage application filed under 35 U.S.C. §371 from International Application No. PCT/US00/32421, filed Dec. 5, 2000, which claims benefit of U.S. Provisional Application 60/171,135, filed Dec. 16, 1999, Japanese Patent Application 377208/99, filed Dec. 28, 1999, and U.S. Provisional Application 60/181,030, filed Feb. 8, 2000, each of which application is 10 entirely incorporated herein by reference.

FIELD OF THE INVENTION

This invention is in the field of human medicine. In 15 particular, this invention is in the field of pharmaceutical compositions for treating various diseases, including diabetes and hyperglycemia.

BACKGROUND OF THE INVENTION

Many polypeptide pharmaceutical compositions are utilized for the treatment of diseases in humans and other mammals. Due to their high lability following oral delivery, polypeptide drugs must generally be delivered by parenteral routes. Chief among these routes are subcutaneous, intramuscular and intravenous.

Polypeptide drug products are traditionally supplied to pharmacies, hospitals and patients as solutions, suspensions, or lyophilized products. In liquid form, each polypeptide 30 drug formulation requires a certain minimum level of chemical and physical stability for a defined length of time governed by treatment regimen, patient convenience, patient safety and regulatory guidelines.

To avoid pain or possible tissue damage, liquid polypeptide drug compositions are designed to provide tonicity or osmolarity close to that of the bodily fluids at or surrounding the site of administration. Excipients such as glycerin, dextrose, mannitol, lactose and salts such as sodium chloride are often used for this purpose. Examples of polypeptide 40 drug products employing glycerin as an isotonicity agent include those comprising as active agent human insulin, insulin lispro, insulin aspart and glucagon.

Glycerin has also been used in pharmaceutical compositions as a solubilizer, wetting agent, emulsifier, solvent, 45 bulking substance, antioxidant, chelating agent and preservative [Spiegel, A. J., et al., J. Pharm. Sci. 52:917–927 (1963); Wang, Y-C. J, et al., J. Parenteral Drug Assoc. 34:452–462 (1980); Remington's Pharmaceutical Sciences, Mack Publishing Company 18th Edition, p. 1316 (1990); Li, 50 S., et al., J. Pharm. Sci. 85:868–872 (1996); Sieger, G. M., et al., U.S. Pat. No. 4,016,273, issued 5 Apr. 1977; Heinz, D. N., WIPO publication WO98/29131, 9 Jul. 1998].

For some polypeptide formulations, physical instability precludes the use of salts for isotonicity, a problem often 55 solved by employing glycerin. Glycerin, however, is known to contribute to chemical instability in polypeptide products. In particular, impurities present in glycerin, such as aldehydes, are believed to initiate covalent crosslinking reactions leading to polypeptide dimers and polymers. See, for 60 example, Bello, J., et al. [Arch. Biochem. Biophys. 172: 608–610 (1976)]. For insulin products, such dimers and polymers have been linked to antigenicity and cutaneous allergy as described in Robbins, D. C., et al. [Diabetes 36:838–841 (1987)]; Robbins, D. C., et al. [Diabetes 65

2

9:727–734 (1992)] concluded that covalent insulin dimers and polymers should be minimized to avoid these allergic reactions but no methods to achieve this goal were disclosed or suggested.

Three observations may be made about the problem of preparing reliably stable polypeptide compositions containing glycerin for parenteral administration. First, there has been a lack of a simple but accurate assay for determining the level of reactive aldehydes present in glycerin that lead to crosslinked polypeptide impurities. Second, there has been no teaching or suggestion in the prior art that commercial lots of glycerin manufactured from different sources should be evaluated to determine if certain sources are better than others in minimizing the polypeptide crosslinking reactions. Third, there has been no convenient, efficient way of lowering the reactive aldehyde content of glycerin to eliminate or minimize the aldehyde-induced crosslinking reactions in aqueous, pharmaceutical polypeptide compositions. Each of these three observations will now be described in 20 more detail.

Measuring Reactive Aldehydes in Glycerin

The lack of a simple, reliable method of measuring the reactive aldehyde impurities in glycerin that lead to formation of crosslinked polypeptide impurities has hindered solution of the polypeptide crosslinking problem in formulations containing glycerin.

Formaldehyde can initiate crosslinking of polypeptides by a reactive imine link [Schwendeman, S. P., et al., PNAS 92:11234–11238 (1995) and Fraenkel-Conrat, H., et al., JACS 70:2673–2684 (1948)]. Glyceraldehyde and glycolaldehyde react with amino groups in polypeptide solutions, forming crosslinked polypeptides as described in Acharya, A. S., et al. [PNAS 80:3590–3594 (1983)] and Acharya, A. S., et al. [Biochemistry 27:4522–4629 (1988)].

Aldehyde impurities in glycerol were speculated to be involved in formation of high molecular weight polymers in insulin formulations [Brange J., et al., Pharm. Res. 9:727–734 (1992); Brange, J., Stability of Insulin, Kluwer Academic Publishers, Boston, pp. 23–36 (1994); Brange, J., et al., Hormone Drugs, Published by the US Pharmacopoeial Convention, Rockville, Md., pp. 95–105 (1982)] but no methods to quantitate or remove the aldehyde impurities to improve chemical stability of the insulin formulations were disclosed.

There are many assays for aldehydes in the literature, but their applicability to measuring the reactive aldehyde content of glycerin as a predictor of polypeptide crosslinking in pharmaceutical formulations is questionable.

The European Pharmacopoeia Supplement 2000 [Council of Europe, Strasbourg, France, pp. 747–751 (1999)] describes an aldehyde test in its glycerol monograph. This test employs pararosaniline hydrochloride reagent and a 5 ppm formaldehyde standard solution as the comparator.

The British Pharmacopoeia 1999 [British Pharmacopoeia Commission, London, pp. 710–711 (1999)] discloses a test for aldehydes and reducing substances in glycerin using pararosaniline hydrochloride and visual comparison with a standard solution containing 5 ppm of formaldehyde.

The "Purpald" reagent, 4-amino-3-hydrazino-5-mercapto-1,2,4-triazole [Dickinson, R. G., et al., Chem. Commun. p. 1719 (1970)] reacts with aldehydes and has been used for determination of formaldehyde in air, glycols,

3

Information Bulletin No. AL-145, Aldrich Chemical Co.; Hopps, H. B., Aldrichimica Acta 33:28-29 (2000)].

The reaction of formaldehyde with acetylacetone to form a colored product was described by Nash, T. [Biochem. J. 55:416-425 (1953)]. This reagent appeared to be fairly 5 specific for formaldehyde, as interference from acetaldehyde was only 1% on a molar basis.

The glycerol monograph of The International Pharmacopoeia [Third Edition, WHO, 4:176-181 (1994)], described a test for aldehydes and reducing substances using fuchsin/ sulfurous acid solution. Color intensity was compared to a 0.2 M solution of potassium permanganate.

In a promotional bulletin entitled "Discover the Origins of Some of the World's Most Consistently Pure Products; Synthetic Glycerine Products" by Dow Chemical Company 15 (Freeport, Tex., USA), pp. 10-11, UV spectroscopy is used to compare OPTIMTM Glycerine 99.7% USP with less pure glycerin samples. No quantitative assessment of the level of aldehydes or other organic impurities is provided.

Glyceraldehyde reacts with 3-methyl-2-benzothiazoli- 20 none hydrazone hydrochloride (MBTH). In Sawicki, E., et al. [Anal. Chem. 33:93–96 (1961)] this reagent was shown to react with DL-glyceraldehyde, but only measurement of formaldehyde in auto exhaust fumes and polluted air was disclosed. Paz, M. A., et al. [Arch. Biochem. Biophys. 25 109:548–559 (1965)] showed that L-glyceraldehyde reacted with MBTH and disclosed an assay to detect trace quantities of aldehydes in the presence of ketones, keto acids and various types of pyranose carbohydrates during biochemical reactions. Eberhardt, M. A., et al. [Marine Chemistry 30 17:199–212 (1985)] disclosed the use of MBTH to measure aldehydes, especially formaldehyde, in seawater and bacterial cultures. MBTH is utilized in a commercial assay using glutaraldehyde, or 1,5-pentanedial [Glutaraldehyde Test Kit Model GT-1, Hach (Loveland, Colo., USA)] as a standard. 35 This test uses a color wheel for measuring glutaraldehyde levels as low as 1 mg/L.

Bailey, B. W., et al. [Anal. Chem. 43:782-784 (1971)] showed the reagent p-phenylenediamine reacted with formaldehyde, acetaldehyde and benzaldehyde but was highly 40 selective for formaldehyde. It was used to measure low concentrations of formaldehyde in air.

We have surprisingly discovered a novel MBTH Test using glyceraldehyde as a standard that can be effectively used to accurately determine the level of reactive aldehydes 45 present in glycerin samples. We have also discovered that the level of crosslinking in polypeptide formulations containing glycerin is strongly correlated in a linear relationship with the level of reactive aldehyde in the glycerin used to prepare the formulations as measured by the aforementioned 50 assay. Thus, our novel MBTH Test may be used to readily predict the relative chemical stability of aqueous, parenteral polypeptide compositions comprising glycerin and may also be employed to select suitable lots of glycerin for use in preparing such compositions.

Glycerin Derived from Various Sources

Another hindrance to solving the polypeptide crosslinking problem in formulations containing glycerin has been the 60 failure to recognize the importance of considering the source from which commercial glycerin is manufactured and the process by which the glycerin is manufactured. In particular, there has been no teaching or suggestion that commercial lots of glycerin manufactured from different sources should 65 reactive aldehydes before or after this treatment. The low-

Aldehydes in glycerin form by autocatalytic or thermal oxidation, as noted in Mohr, J., et al. [Canadian Patent Application 2,242,591, published 13 Jul. 1998]. As reported by Ziels, N. W. [J. Amer. Oil Chemists' Soc. 33:556–565 (1956)], the processes used to commercially manufacture and purify glycerin have a great impact on the final purity of the glycerin, regardless of the starting material. Glycerin has been manufactured from many sources, including animal fat, plants, fermentation, chemical synthesis from smaller organic molecules and from propylene. Methods of manufacturing glycerin from these and other sources are well known to those skilled in the art. However, what influence the source has on the level of reactive aldehydes found in lots of commercially manufactured glycerin and on the ultimate chemical stability of aqueous, parenteral polypeptide compositions comprising glycerin has not been explored or determined.

Rohde, T. D., et al. [Trans. Am. Soc. Artif. Intern. Organs, 33:316-318 (1987)] disclosed a new insulin formulation for use in implantable pumps containing about 80% glycerin in which the animal-rendered glycerin used in previous formulations was replaced with glycerin from an unspecified synthetic source that was further purified by the authors using a mixed bed ion exchange column. The new and previous formulations also differed in pH, a key factor influencing extent of crosslinking reactions in insulin formulations. In treating diabetic patients, a longer flow cycle and lower insulin usage with the new formulation suggested improved stability, which was attributed to the difference in pH and the synthetic glycerin's extra purification.

Using the MBTH Test described herein, we have most surprisingly discovered that commercial glycerin lots manufactured from non-animal sources contain lower levels of reactive aldehydes than animal-derived glycerin. This was demonstrated for glycerin derived from plants and propylene. Glycerin derived from propylene has particularly low levels of reactive aldehydes. We also discovered that commercially manufactured glycerin lots derived from plant and propylene sources have a much lower average reactive aldehyde content per month of age than glycerin lots derived from animal sources, which suggests the level of reactive aldehydes increases faster over time in animal derived glycerin than in plant and propylene derived glycerin.

Furthermore, we discovered that aqueous, parenteral pharmaceutical compositions of polypeptides comprising glycerin derived from propylene have improved chemical stability compared to similar compositions prepared with animal derived glycerin.

Lowering Reactive Aldehyde Levels in Glycerin

Finally, no simple, efficient method for lowering the level of reactive aldehydes in glycerin to improve the chemical 55 stability of pharmaceutical polypeptide compositions comprising glycerin has been disclosed.

Bello, J. [Biochemistry 8:4535-4541 (1969)] and Bello, J., et al. [Arch. Biochem. Biophys. 172:608–610 (1976)] sought to prevent crosslinking in a protein solution containing glycerin by purifying the glycerin. The glycerin was first treated with the reducing agent sodium borohydride. The reduction step was followed by treating the glycerin with MB-3 resin to remove inorganic salts, and finally by distillation in vacuo. There was no indication of the level of



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

